A Agilent Technologies Inc.

Agilent Technologies Introduces New GC/Q-TOF System Enabling Greater Exploration of Unknown Chemical Samples

Agilent Technologies Inc. (NYSE:A) today introduced a new high-resolution, accurate-mass system designed for laboratories doing food and environmental testing, life science research, forensics and chemical analysis.

The Agilent 7250 GC/G-TOF system combines gas chromatography and quadrupole time-of-flight mass spectrometry with a Low Energy Electron Ionization source that enables greater exploration of unknown chemical samples. The Agilent 7250 GC/Q-TOF system is being showcased at the ASMS conference being held June 3 through June 8 in Indianapolis, Indiana.

The new system represents the only commercially available combination of a high-resolution, accurate-mass GC/MS and low-energy ionization source, making it possible for scientists to employ analytical techniques that were not previously practical, or in some cases even possible.

The capabilities of the 7250 GC/Q-TOF system will now allow labs to quickly and easily identify volatile and semi-volatile compounds that, in the past, would require them to perform alternative techniques, or longer sample preparations to detect and determine the compounds present in their samples. Furthermore, with Low Energy Electron Ionization, scientists will be better able to elucidate chemical structures.

“The 7250 allows users to implement a range of GC/MS experiments that are difficult to execute accurately with other GC/MS technologies,” said Monty Benefiel, vice president and general manager of Agilent’s Mass Spectrometry Division. “It is an excellent fit for labs that need a combination of fast scanning, high resolution and accurate mass information from a single analysis—a combination where Q-TOF mass spectrometry excels.”

Agilent offers a range of GC/MS technologies for both qualitative and quantitative analysis across a wide variety of applications.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A), is a global leader in analytical laboratory technologies. With more than 50 years of insight and innovation, our instruments, software, services, solutions and people provide trusted answers to our customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch